Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

Irinotecan and cisplatin demonstrated promising outcomes in extensive-stage small-cell lung cancer. According to the dosage and schedule of irinotecan, efficacy and toxicity profiles showed subtle differences. This study was designed to evaluate efficacy and toxicity of 3-week schedule of irinotecan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Y S, Lee, H R, Park, S, Lee, S C, Hwang, I G, Park, B-B, Lee, J, Ahn, J S, Ahn, M-J, Lim, H Y, Park, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360764/
https://www.ncbi.nlm.nih.gov/pubmed/17133266
http://dx.doi.org/10.1038/sj.bjc.6603500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360764/
https://www.ncbi.nlm.nih.gov/pubmed/17133266
http://dx.doi.org/10.1038/sj.bjc.6603500

Ejemplares similares